Giovanni Caforio, Bristol Myers Squibb CEO (Pablo Martinez Monsivais/AP Images)
April 29, 2021 10:24 AM EDTUpdated 04:07 PM
Pharma

Star­ing at a down quar­ter for Op­di­vo, Bris­tol My­ers keeps its eyes on price com­pe­ti­tion po­ten­tial in packed PD-1 mar­ket

Kyle Blankenship

De­spite its stand­ing as one of the best­selling an­ti-PD-1s, Bris­tol My­ers Squibb can ill af­ford a down quar­ter for its lead­ing I/O amid a packed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times